PBYI Puma Biotechnology Inc

37.65
+0  (1%)
Previous Close 37.25
Open 37.50
Price To book 6.54
Market Cap 1.39B
Shares 36,951,000
Volume 735,868
Short Ratio 5.91
Av. Daily Volume 983,661

SEC filingsSee all SEC filings

  1. 8-K - Current report 17768022
  2. 8-K - Current report 17746480
  3. 8-K - Current report 17713353
  4. 8-K - Current report 17655083
  5. 8-K - Current report 17654556

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Note this trial is conducted by competitor Roche (RHHBY), NOT by Puma. The event was likely to have a significant impact on the share price of Puma (e.g. positive data would likely have a negative impact on Puma and vice versa). Data were released March 2, 2017 - primary endpoint was met. Late breaker at ASCO - June 5, 2017. Abstract LBA500.
Roche (RHHBY) - Perjeta + Herceptin (APHINITY)
Adjuvant HER2+ breast cancer
Phase 2 data due 2Q 2017.
Neratinib
HER2-positive metastatic breast cancer patients with brain metastases
Phase 3 planned
Neratinib plus temsirolimus
Fourth line HER2-positive metastatic breast cancer
Phase 2 biomarker data released December 7, 2016. Further interim data due 2Q 2017.
PB272 (NSABP FB-7)
Neoadjuvant treatment for patients with HER2-positive breast cancer
Phase 2 preliminary data released December 8, 2016 with further data presented April 2, 2017.
Neratinib SUMMIT
HER2 non-amplified breast cancer that has a HER2 mutation
Phase 2 additional data released December 8 2016 and April 4, 2017. Noted high rates of diarrhea.
Neratinib monotherapy with high dose loperamide prophylaxis - CONTROL
Extended adjuvant treatment of early stage HER2-positive breast cancer
Phase 3 data due 1H 2017.
Neratinib
Third-line HER2-positive metastatic breast cancer
Phase 2 completed.
Neratinib - NEfERTT trial
HER2-positive breast cancer first line
Noted April 17, 2017 that Advisory Committee Meeting has been scheduled for May 24, 2017. Announced acceptance of NDA Filing September 20, 2016. PDUFA estimate July 20, 2017.
PB272 ExteNET trial
Extended adjuvant HER2-positive early stage breast cancer

Latest News

  1. Shortened FDA Advisory Panel Is Bad Omen for Puma Bio's Controversial Breast Cancer Drug
  2. Puma Biotechnology Announces FDA Advisory Committee to Review Neratinib for the Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
  3. Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of PB272 in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2017 AACR Annual Meeting
  4. Puma Biotechnology Presents Interim Results of Phase Ib/II FB-10 Trial of PB272 in Combination with Trastuzumab Emtansine (T-DM1) in HER2-Positive Metastatic Breast Cancer at the 2017 AACR Annual Meeting
  5. Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of PB272 for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Cancer at the 2017 AACR Annual Meeting
  6. Puma Biotechnology Launches Expanded Access Program for PB272 (Neratinib) for U.S. Patients with HER2-Positive Breast Cancer or HER2-Mutated Cancers
  7. Finding Bullish and Bearish Market Reversals
  8. 7 Stocks Trending Up With Monster Volume
  9. Puma Leads Massive Biotech Surge As Esperion Hits 15-Month High
  10. Kroger, Shake Shack and Puma dip; Monster Beverage gains
  11. Puma (PBYI) Q4 Loss Wider than Expected, Neratinib in Focus
  12. Why Puma Biotechnology Inc. Got Hammered Today
  13. Puma Biotechnology to Present at Cowen’s Health Care Conference
  14. Puma Plunges on Breast Cancer Drug Update
  15. Top Biotech Stocks With FDA Decisions in 2017
  16. Puma Biotech shares plummet 26% after Roche reports positive results for late-stage breast cancer drug
  17. Roche Shares Soar, Puma Bio Sinks on Perjeta Breast Cancer Study Win
  18. Puma Biotechnology Announces Publication of Abstracts on Neratinib for the AACR Annual Meeting 2017
  19. Puma Biotechnology Provides Update on Review of Marketing Authorisation Application for PB272